102 related articles for article (PubMed ID: 17203165)
1. Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.
Tai HL; Lin TS; Huang HH; Lin TY; Chou MC; Chiou SH; Chow KC
Oncol Rep; 2007 Feb; 17(2):305-11. PubMed ID: 17203165
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer.
Huang KH; Chiou SH; Chow KC; Lin TY; Chang HW; Chiang IP; Lee MC
Histopathology; 2010 Sep; 57(3):384-94. PubMed ID: 20840669
[TBL] [Abstract][Full Text] [Related]
3. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer.
Cui L; Wang Y; Shi Y; Zhang Z; Xia Y; Sun H; Wang S; Chen J; Zhang W; Lu Q; Song L; Wei Q; Zhang R; Wang X
Proteomics; 2007 Nov; 7(22):4192-202. PubMed ID: 17994624
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
6. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
9. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
[TBL] [Abstract][Full Text] [Related]
10. Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters.
Rodríguez Faba O; Fernández Gómez JM; Palou Redorta J; Escaf Barmadah S; Vizoso F; Villavicencio Mavrich H
Urol Int; 2007; 78(2):140-4. PubMed ID: 17293654
[TBL] [Abstract][Full Text] [Related]
11. [Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].
Wu DL; Zhang YF; Guan M; Liu WW; Xu YM; Jin SB; Zhang J; Jin CR; Lü Y
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):274-7. PubMed ID: 17760254
[TBL] [Abstract][Full Text] [Related]
12. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
14. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes.
Wang X; Colby JK; Rengel RC; Fischer SM; Clinton SK; Klein RD
Mol Carcinog; 2009 Jan; 48(1):1-13. PubMed ID: 18444251
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan.
Chen CH; Chiou HY; Hsueh YM; Chen CJ; Yu HJ; Pu YS
J Urol; 2009 Feb; 181(2):547-52; discussion 553. PubMed ID: 19084863
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
19. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridization study of arsenic-exposed and non-arsenic-exposed urinary transitional cell carcinoma.
Hsu LI; Chiu AW; Pu YS; Wang YH; Huan SK; Hsiao CH; Hsieh FI; Chen CJ
Toxicol Appl Pharmacol; 2008 Mar; 227(2):229-38. PubMed ID: 18201742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
